INTRODUCTION

Phenotypic classification of functional CD8
ϩ T cells, such as naïve, memory, and effector T cells, is useful in various T cell studies using mouse or human cells. In humans, the particular expression patterns of costimulatory molecules CD27 and CD28 as well as CD45RA or CD45RO are associated with naïve, memory, and effector functions of CD8 ϩ T cells [1] [2] [3] [4] [5] [6] [7] . A recent study examining the expression of CD27, CD28, and CD45RA demonstrated that CD8 ϩ T cells expressing the phenotypes of CD27 Ϫ CD28 Ϫ CD45RA ϩ/Ϫ and CD27 low CD28 Ϫ -CD45RA
ϩ/Ϫ could be classified into effector and memory/ effector cells, respectively, and naïve and memory CD8 ϩ T cells are phenotypically CD27 ϩ CD28 ϩ
CD45RA
ϩ and CD27 ϩ -CD28 ϩ CD45RA Ϫ , respectively [8] . Chemokine receptors are also useful to discriminate functional subsets among human CD8 ϩ T cells. CC chemokine receptor 7 (CCR7) is expressed on naïve CD8
ϩ T cells as well as on undifferentiated memory CD8 ϩ T cells, called central memory T cells, although it also plays an important role as a receptor for homing to secondary lymphoid tissues [1, 2, 9, 10] . CCR5 is expressed predominantly on memory and memory/effector CD8 ϩ T cells, and its expression decreases during differentiation from memory to effector CD8 ϩ T cells, i.e., CD27
Ϫ [1, 2, 8, 11] . A recent study demonstrated that CXC chemokine receptor 1 (CXCR1) was expressed on effector and effector/memory CD8 ϩ T cells with phenotypes of CD27
ϩ/Ϫ and CD27 low -
CD28
Ϫ CD45RA ϩ/Ϫ , respectively, and that the expression of CXCR1 was correlated with that of perforin [12] . CX3CR1 is another marker of effector CD8 ϩ T cells [13] , and it was recently shown that CXCR4 is expressed predominantly on CD8 ϩ T cells with the naïve CD27 ϩ CD28 ϩ CD45RA ϩ phenotype and that this receptor is down-regulated during differentiation from CD8 ϩ T cells with a memory phenotype to those with an effector phenotype [14] .
The chemokine receptor CXCR3 is reported to be expressed on a subset of B and T cells [15] [16] [17] [18] [19] . CXCR3-mediated chemotaxis of these cells in response to its ligands, i.e., CXC chemokine ligand 9 (CXCL9)/monokine induced by interferon-␥ (IFN-␥; Mig), CXCL10/IFN-␥-inducible protein 10 (IP-10), and the CXCL11/IFN-␥-inducible T cell chemokine (I-TAC) [20, 21] . The expression of CXCR3 on CD4 ϩ and CD8 ϩ T cells is enhanced strongly when the cells are activated [22, 23] . In human CD4 ϩ T cells, CXCR3 is expressed at high levels on T helper cell type 0 (Th0) and Th1 cells and at low levels on Th2 cells [24] . In contrast, the populations of human CD8 ϩ T cells expressing CXCR3 have not been studied in detail.
In the present study, we investigated the expression of CXCR3 on CD8 ϩ T cell subsets defined by three surface markers: CD27, CD28, and CD45RA. In addition, we investigated the correlation of the expression of this receptor with that of CCR7 and CCR5 and further analyzed the expression of CXCR3 on Epstein-Barr virus (EBV)-specific and human cytomegalovirus (HCMV)-specific CD8 ϩ T cells by using human leukocyte antigen (HLA)-class I-peptide tetrameric complexes (tetramers). Finally, we characterized the function of CD8 ϩ T cells highly expressing CXCR3.
MATERIALS AND METHODS
Blood samples
Blood samples were taken from healthy adult individuals. For analysis of HCMV-specific and EBV-specific CD8 ϩ T cells, samples were obtained from HCMV-seropositive individuals with HLA-A*0201 or HLA-A*0206 and EBVseropositive individuals with HLA-A*1101, respectively.
Antibodies
Anti-CD27 phycoerythrin (PE)-and allophycocyanin (APC)-Cy7-labeled monoclonal antibody (mAb); anti-CD28 fluorescein isothiocyanate (FITC)-and APC-labeled mAb; anti-CCR5 FITC-labeled mAb; anti-CCR7 PE-Cy7-labeled mAb; anti-CD19 FITC mAb; and anti-mouse-immunoglobulin (IgG) FITC and PE mAb were obtained from BD Biosciences (San Diego, CA). Anti-CXCR3 FITC-and PE-labeled mAb (49801.111 clone) and anti-CD4 APC-labeled mAb were purchased from DakoCytomation (Glostrup, Denmark). Anti-CD45RA energy-coupled dye (ECD)-labeled mAb and anti-CD3 ECD-labeled mAb were purchased from Immunotech (Marseille, France). Anti-CD8 Cascade Blue-labeled mAb was made by conjugating Cascade Blue (Molecular Probes, Eugene, OR) with anti-CD8 mAb OKT8.
HLA-class I tetramer
HLA-class I-peptide tetrameric complexes (tetramers) were synthesized as described previously [25] . The HCMV cytolytic T lymphocyte (CTL) epitope (HCMV-1 pp65 495-503: NLVPMVATV) [26] and the EBV CTL epitope (EBNA3B 416-424: IVTDFSVIK) [27] were used for the refolding of HLA-A*0201 and HLA-A*0206 molecules and HLA-A*1101 molecules, respectively. PE-labeled streptavidin was used for generation of the tetramers (Molecular Probes).
Flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) from healthy individuals were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD19, and anti-CXCR3 mAb for 30 min at 4°C and were then washed twice with phosphate-buffered saline (PBS) containing 10% newborn calf serum (NCS; PBS/10% NCS). After the cells had been washed twice with PBS/10% NCS, the percentage of CXCR3 high and CXCR3 low cells in CD19 ϩ , CD3 ϩ CD4 ϩ , and CD3 ϩ CD8 ϩ subpopulations was measured by using an LSR II (BD Biosciences). CXCR3 ϩ cells were divided into two subsets, i.e., CXCR3
high (Ͼ7/8 of the maximal fluorescence intensity) and CXCR3 low cells (Յ7/8 of the maximal fluorescence intensity). To investigate the CXCR3 expression in each CD27CD28CD45RA subset of total CD8
ϩ T cells, we purified CD8 ϩ T cells from PBMCs by using anti-CD8-coated magnetic beads (Miltenyi Biotec, Gladbach, Germany). The purified CD8 ϩ T cells (Ͼ98%) were stained with anti-CD27, anti-CD28, anti-CD45RA, and anti-CXCR3 mAb for 30 min at 4°C and were then washed twice with PBS/10% NCS. The percentage of CXCR3 high and of CXCR3 low cells in each subset was measured by using a FACSCalibur (BD Biosciences).
To determine CCR7 and CCR5 expression on CXCR3 subsets of total CD8 ϩ T cells, we stained PBMCs with anti-CCR7 mAb for 30 min at room temperature (RT). After they had been washed twice with PBS/10% NCS, the cells were stained with anti-CCR5, anti-CXCR3, and anti-CD8 mAb for 30 min at 4°C. For determination of CXCR3 expression on the CCR7CCR5 subset of each CD27CD28CD45RA subset of CD8 ϩ T cells, we stained PBMCs with anti-CCR7 mAb for 30 min at RT. After having been washed twice with PBS/10% NCS, the cells were stained with anti-CCR5, anti-CD27, anti-CD28, anti-CD45RA, and anti-CXCR3 mAb for 30 min at 4°C. The percentage of CXCR3 high and CXCR3 low cells in each subset was measured by using the LSR II.
To clarify the expression of CXCR3 on HCMV-specific and EBV nuclear antigen 3 B (EBNA3B)-specific CD8 ϩ T cells, we incubated PBMCs with HCMV-HLA-A*0201, HCMV-HLA-A*0206, or EBNA3B-HLA-A*1101 tetramers for 30 min at 37°C. The cells were washed twice with RPMI/10% NCS and then stained with anti-CXCR3, anti-CD27, anti-CD28, anti-CD45RA, and anti-CD8 mAb for 30 min at 4°C. The cells were then washed twice again with PBS/10% NCS.
Cytokine production by CXCR3 high or CXCR3
To measure cytokine production by CXCR3 high or CXCR3 low/-CD27 ϩ CD28 ϩ -CD45RA -CD8 ϩ T cells, we purified CD8 ϩ T cells from PBMCs by using the anti-CD8-coated magnetic beads (Miltenyi Biotec). The purified CD8 ϩ T cells (Ͼ98%) were stained with anti-CD27, anti-CD28, anti-CD45RA, and anti-CXCR3 mAb, and then the CXCR3 high CD27 ϩ CD28 ϩ CD45RA -CD8 ϩ and CXCR3 low/-CD27 ϩ CD28 ϩ CD45RA -CD8 ϩ T cells were separated by a cell sorter (FACSAria, BD Biosciences). Sorted T cell subsets were cultured for 6 h in F-bottom 96-well plates with or without phorbol 12-myristate 13-acetate (PMA; 10 ng/ml)/ionomycin (1 g/ml) in RPMI containing 10% fetal calf serum (FCS; R10 medium). After the first 2 h of incubation, brefeldin A (10 g/ml) was added to each well. The cells were fixed with 4% paraformaldehyde at 4°C for 20 min and then permeabilized at 4°C for 20 min with PBS supplemented with 0.1% saponin containing 20% NCS (permeabilizing buffer). The cells were resuspended in the same buffer and then stained with anti-IFN-␥ and anti-interleukin (IL)-2 mAb at RT for 30 min. Thereafter, they were washed three times in the permeabilizing buffer at 4°C. We also used PE-Cy7-and APC-labeled mouse IgG as an isotype control. The cells were finally resuspended in PBS containing 2% paraformaldehyde, and then the cytokine profile was analyzed by flow cytometry (LSR II, BD Biosciences).
Migration assay
CD8
ϩ T cells were purified from PBMCs by using the anti-CD8-coated magnetic beads (Miltenyi Biotec). The purified CD8 ϩ T cells (Ͼ98%) were stained with anti-CD3, anti-CD8, anti-CD27, and anti-CD28 mAb, and then CD3 ϩ CD8 ϩ CD27 high CD28 -and CD3 ϩ CD8 ϩ CD27 low CD28 -subsets were separated by a cell sorter (FACSAria, BD Biosciences). The chemotaxis of sorted CD8 ϩ T subsets was measured by using a TAXIScan holder [28] (Effector Cell Institute, Tokyo, Japan). The chemotactic assays were performed at RT in RPMI-1640 medium supplemented with 20 mM HEPES and 0.1% bovine serum albumin in the assembled KK chamber. The common space at the top end of the holes was filled with medium, and a 1-l cell suspension (500 cells/l) was injected via a 10-m micro-syringe into one of the two compartments through a central hole. To adjust the position of the cells in the compartment and align them along the start line on the edge of the channel, we withdrew the medium with a 10-l micro-syringe from the other central hole provided for the opposite compartment immediately after injection of the cells. By drawing out the medium in the common space and then more at the appropriate velocity described below, we caused the cells to begin to flow to reach the vicinity of the micro-channel. We stopped drawing medium when ϳ100 cells had become aligned on the edge of the channel. After alignment of the cells, a compensatory amount of medium was used for refilling to prevent migration of the contents through the channel.
A chemokine was injected in the compartment opposite that containing the cells by using a 10-m micro-syringe. Chemokines used in the experiments were 100 g/ml human recombinant Mig and 1 M stromal cell-derived factor 1␣ (SDF-1␣; PeproTech House, London, UK) as a positive control. To observe and record the migration of cells in the channel, we used a charged-coupled device camera connected to a monitor display. When the chemotaxis of sorted cells was examined, the glass plate was coated with RPMI 1640 containing 40% FCS before assembly of the KK-chamber. After 60 min, we counted the number of sorted cells that migrated toward the middle of the channel by using a TAXIScan analyzer (Effector Cell Institute).
RESULTS
Surface expression of CXCR3 on human CD8
ϩ
T cells
To analyze the expression of CXCR3 on lymphocytes, we stained PBMCs from healthy individuals with anti-CD4, anti-CD8, anti-CD3, and anti-CXCR3 mAb. A representative result of the flow cytometry analysis is shown in Figure 1A . Peripheral lymphocytes could be classified into three subsets (CXCR3 high , CXCR3 low , and CXCR3 Ϫ ) by the levels of CXCR3 expression. The results from eight healthy individuals showed that ϳ70% of them were CXCR3 Ϫ ones. Conversely, as shown in Figure 1, A 
ϩ naïve subsets ( Fig. 2A) , suggesting that CXCR3 is highly expressed on the memory subset and that its surface expression is up-regulated during differentiation from naïve to memory CD8 ϩ T cells or from effector to memory CD8 ϩ T cells. We inversely analyzed the CD27CD28CD45RA expression on CXCR3 high CD8 ϩ T cells. Approximately 50%, 20%, and 20% of CXCR3 high CD8
ϩ T cells were CD27 (Fig. 2B) , indicating that up-regulation of CXCR3 had already started in some of the CD8 ϩ T cells expressing the naïve phenotype.
Coexpression of CXCR3, CCR7, and CCR5 on CD8 ϩ T cells CCR7 is expressed on naïve CD8 ϩ T cells and on central memory CD8
ϩ T cells [8, 9] , whereas CCR5 is expressed predominantly on a subset in memory CD8 ϩ T cells [1, 8] . To clarify the relationship between the expression of these two receptors and CXCR3, we investigated the coexpression of CXCR3 and CCR7 or CCR5 on CD8 ϩ T cells from four healthy individuals. CXCR3 high cells were found predominantly in CCR7 Ϫ and CCR5 Ϫ subsets (Fig. 3, A and B) , implying that most CXCR3 high CD8 ϩ T cells did not express CCR7 or CCR5 on their surface. We also directly analyzed the coexpression of these three receptors on CD8 ϩ T cells from the same individual. A representative result is shown in Figure 3C . The CD8 ϩ T cells could be classified into three groups on the basis of the expression pattern of CCR7 and CCR5: CCR7 ϩ CCR5 Ϫ , CCR7 individuals by seven-color flow cytometric analysis with anti-CXCR3, anti-CCR5, anti-CCR7, anti-CD45RA, anti-CD27, anti-CD28, and anti-CD8 mAb (Fig. 4) [1] . Therefore, we hypothesized that some of the former cells would express high levels of CXCR3 and the latter, only low levels or none at all. So we examined the CXCR3 expression on EBNA3B-specific and HCMV-specific ϩ healthy individuals were stained with the combination of anti-CD8 and anti-CXCR3 mAb as well as the tetramer or with that of anti-CD8, anti-CD27, anti-CD28, and anti-CD45RA mAb as well as the tetramer. All EBV-specific CD8 ϩ T cells, which were mostly of the CD27 ϩ CD28 ϩ CD45RA Ϫ phenotype, were contained in CXCR3 high and CXCR3 low subsets, although the number in the latter subset was approximately twice that in the former (Fig.  5A) (Fig. 5B) . These findings were confirmed in EBNA3B-specific and HCMV-specific CD8 ϩ T cells from five healthy individuals. The results from these individuals showed that ϳ45% of EBNA3B-specific CD8 ϩ T cells were CXCR3 high cells, whereas they were hardly detected in HCMV-specific CD8 ϩ T cells (Fig. 5C) 
CXCR3
high and CXCR3 low/-subsets of CD27
ϩ T cells and then measured IL-2 and IFN-␥ production of these sorted cells after having stimulated them with PMA and ionomycin (Fig. 6) . The purities of the sorted CXCR3 high and CXCR3 low cells were 96.0% and 98.7%, respectively. The CXCR3 high cells produced IL-2 and IFN-␥, suggesting that the CXCR3 high cells were memory CD8 ϩ T cells possessing the ability to produce both cytokines. Conversely, the CXCR3 low/-cells contained four populations producing IL-2, IFN-␥, both of them, or neither of them, indicating that at least four functionally different subpopulations exist in the CXCR3 low/-cell population. The naïve CD8 ϩ T cell subset included both cells producing only IL-2 and those producing neither IL-2 nor IFN-␥, whereas the effector subset included both cells producing only IFN-␥ and those producing neither IL-2 nor IFN-␥. These results together suggest that the CXCR3 low/-cells producing only IL-2 were immature memory cells and that the CXCR3 low/-cells producing only IFN-␥ were effector cells. The cells that failed to produce either cytokine may have been immature memory cells or well-differentiated, mature effector cells. These results were confirmed in an experiment using the cells from a different individual (data not shown 
CD8
ϩ T cells were sorted from PBMCs of a healthy individual, and then the migration of the sorted cells induced by the CXCR3 ligand Mig or the CXCR4 ligand SDF-1 was measured by using a TAXIScan holder (Fig.  7) 
CD28
Ϫ CD8 ϩ and CD27 low CD28 Ϫ CD8 ϩ T cells [14] . Indeed, there was no difference between the chemotactic response of two cell populations to SDF-1. The above results were confirmed in an experiment using cells from a different individual (data not shown). These findings indicate that CXCR3 high CD8 ϩ T subsets had a strong ability to migrate in response to CXCR3 ligands.
DISCUSSION
Previous studies demonstrated that a subset of CD8 ϩ and CD4 ϩ T cells expresses CXCR3 [16] . However, these studies did not address the level of CXCR3 on the cells. We here showed that CXCR3 high cells were found in a small subset of CD8 ϩ and CD4 ϩ T cells. CXCR3 high cells were detected predominantly in CD8 ϩ T cells carrying the CD27
ϩ/Ϫ phenotype, whereas they were rarely detected in CD8 ϩ T cells carrying the CD27 ϩ -CD28 ϩ CD45RA ϩ naive phenotype. Conversely, the analysis of CD27CD28CD45RA expression on CXCR3 high CD8 ϩ T cells (Fig. 2B) revealed that ϳ60% and 15% of CXCR3 high CD8
ϩ T cells expressed CD27 ϩ
CD28
ϩ CD45RA Ϫ memory and CD27 ϩ -CD28 ϩ CD45RA ϩ naïve phenotypes, respectively, suggesting that the up-regulation of CXCR3 expression starts in some of the immature CD8 ϩ T cells carrying the CD27 ϩ CD28 ϩ -CD45RA ϩ naïve phenotype. The findings that these CD27 ϩ -CD28 ϩ CD45RA ϩ CD8 ϩ T cells expressed CCR7 but not CCR5 (Fig. 4) support the idea that they are a part of the naïve cell population, although the possibility that they are central memory cells cannot be excluded. In the CD8 ϩ T cells expressing the CD27 ϩ CD28 ϩ CD45RA Ϫ memory phenotype, CXCR3 high cells were found predominantly in CCR7 ply that the up-regulation of CXCR3 starts in some of the naïve cells or central memory cells expressing the naïve CD27CD28CD45RA phenotype and then expands in central memory cells and relatively immature memory cells (Fig. 8) . CD8 ϩ T cells producing IFN-␥ but not IL-2 were found among the CD8 ϩ T cells carrying the effector phenotype but not among those with the naïve phenotype (Fig. 5) . Previous studies demonstrated that CD8 ϩ T cells displaying the effector phenotype, CD45RA ϩ CCR7 Ϫ or CD45RA ϩ CD27 Ϫ , produce IFN-␥ but not IL-2 [29, 30] , indicating that CD8 ϩ T cells having the ability to produce IFN-␥ but not IL-2 are effector CD8 ϩ T cells. In contrast, CD8 ϩ T cells producing IL-2 but not IFN-␥ were found among those with the naive phenotype but not in those showing the effector one (Fig. 5) . This finding indicates that CD8 ϩ T cells having the ability to produce IL-2 but not IFN-␥ are immature cells. Therefore, it is likely that CD8 ϩ T cells that can produce IFN-␥ and IL-2 are more mature cells than those that are able to produce IL-2 but not IFN-␥. The CXCR3 low/Ϫ CD8 ϩ T cells carrying the CD27 ϩ -CD28 ϩ CD45RA Ϫ phenotype included four populations, i.e., those producing IL-2, IFN-␥, both, and neither (Fig. 5) 
CD8
ϩ T cells were then isolated by using a cell sorter. The sorted CD8 ϩ T cells were cultured for 6 h in F-bottom 96-well plates in R10 medium containing PMA (10 ng/ml) and ionomycin (1 g/ml). IFN-␥-and IL-2-producing cells were analyzed by flow cytometry. Sorting purities of CD27 Ϫ subsets of CD8 ϩ T cells were separated by using a cell sorter. CXCR3 expression on both sorted subsets was confirmed simultaneously by staining with anti-CXCR3 mAb. The chemotactic responses of CD27 high -CD28 Ϫ and CD27 low CD28 Ϫ subsets were analyzed by using the TAXIScan (Effector Cell Institute). The migration was induced by 100 g/ml Mig (red line) and SDF-1 (green line), as a positive control is also shown.
can produce IL-2 or not, because if these cells can do so, the up-regulation of CXCR3 would be an event in restricted populations such as naïve T cells having the ability to produce IL-2 and memory T cells possessing the ability to produce IL-2 and IFN-␥. However, this experiment using purified CXCR3 high -CD8 ϩ T cells with the CD27 The physiological importance of high expression of CXCR3 on memory CD8 ϩ T cells is unknown. IFN-␥-induced chemokines such as Mig, IP-10, and I-TAC are ligands for CXCR3 and can be produced by various cells including macrophages, neutrophils, and bronchial epithelial cells [31] [32] [33] . As the expression of these chemokines is induced by IFN-␥, they are to be produced mostly at sites of inflammation. A recent study found an increase in Ca 2ϩ flux in response to a low level of IP-10 in Th1 CD4 ϩ T cells, which expressed CXCR3 at high levels, but not in Th2 CD4 ϩ T cells, which expressed CXCR3 at low levels, thus indicating that the level of the chemokine receptor expression determines the sensitivity to CXCR3 ligands [24] . The expression level of CXCR3 on CXCR3 high cells was approximately tenfold higher than that on CXCR3 low cells. The present study demonstrates that the migration capacity of CXCR3 ϩ cells was dependent on the expression level of CXCR3 on these cells, suggesting that CXCR3 high memory T cells might migrate more actively to inflammatory sites in response to CXCR3 ligands than CXCR3 low T cells. As CXCR3 high memory CD8 ϩ T cells do not express CCR5, the migration of these cells by the ligands for CCR5 is not expected. Therefore, it is suggested that high expression of CXCR3 is an important event in migration of these memory CD8 ϩ T cells to sites of inflammation. In addition, as Th1 cells expressing a high level of CXCR3 are thought to actively migrate to inflammatory sites in response to CXCR3 ligands, they may help memory CD8 ϩ T cells to differentiate into effector CD8 ϩ T cells in these sites. Especially, the help of CD4 ϩ Th cells may be necessary for CCR7 ϩ CXCR3 high immature memory CD8 ϩ T cells to differentiate to effector cells. These CXCR3 high CD8 ϩ and CD4 ϩ T cells together may induce T cell proliferation by stimulation with cytokines such as IL-2 from these cells and may be involved in the suppression of viral replication by producing effector CD8 ϩ T cells and various cytokines after their migration to the inflammatory sites.
In summary, the present study revealed that CXCR3 was expressed predominantly on a part of CD8 ϩ T cell populations with naïve and memory phenotypes, especially on CCR7 ϩ T cell subsets was studied previously [12, 14] , and perforin expression was reported to occur in effector CD8 ϩ T cell subsets [8] .
